HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice.

Saved in:

Bibliographic Details
Title:	HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice.
Authors:	Tyagi RK; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States., Jacobse J; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, Netherlands., Li J; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States., Allaman MM; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States., Otipoby KL; Pandion Therapeutics, Immunology Department, Watertown, MA, United States., Sampson ER; Pandion Therapeutics, Immunology Department, Watertown, MA, United States., Wilson KT; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.; Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, TN, United States.; Center for Mucosal Inflammation and Cancer, Vanderbilt University Medical Center, Nashville, TN, United States.; Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, United States., Goettel JA; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.; Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, TN, United States.; Center for Mucosal Inflammation and Cancer, Vanderbilt University Medical Center, Nashville, TN, United States.
Source:	Frontiers in immunology [Front Immunol] 2021 Feb 24; Vol. 12, pp. 630204. Date of Electronic Publication: 2021 Feb 24 (Print Publication: 2021).
Publication Type:	Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2021.630204